What is the recommended management plan for migraines, including acute abortive therapy, preventive medication, and lifestyle measures?

Management of Migraines

For acute migraine treatment, start with NSAIDs (ibuprofen 400–800 mg or naproxen 500–825 mg) for mild-to-moderate attacks, escalate to triptans (sumatriptan 50–100 mg) for moderate-to-severe attacks or NSAID failure, and strictly limit all acute medications to ≤2 days per week to prevent medication-overuse headache. 1

Acute Abortive Therapy

First-Line Treatment Algorithm

• Mild-to-moderate migraine: Begin with NSAIDs—ibuprofen 400–800 mg, naproxen sodium 500–825 mg, or aspirin 1000 mg—taken at the earliest sign of headache while pain is still mild. 1
• Moderate-to-severe migraine or NSAID failure after 2–3 episodes: Add a triptan to the NSAID regimen (sumatriptan 50–100 mg PLUS naproxen 500 mg), which is superior to either agent alone and provides 130 additional patients per 1,000 achieving sustained pain relief at 48 hours. 1
• Combination therapy with acetaminophen-aspirin-caffeine (1000 mg/500–1000 mg/130 mg) is an alternative first-line option for mild-to-moderate attacks, achieving pain reduction in 59.3% of patients at 2 hours. 1

Triptan Selection and Route Optimization

• Oral triptans with strong evidence: sumatriptan 50–100 mg, rizatriptan 10 mg (fastest oral triptan, reaching peak in 60–90 minutes), eletriptan 40 mg, zolmitriptan 2.5–5 mg, and naratriptan (longest half-life to reduce recurrence). 1
• If one triptan fails after 2–3 episodes, try a different triptan—failure of one does not predict failure of others. 1
• For rapid progression to peak intensity or prominent nausea/vomiting: Use subcutaneous sumatriptan 6 mg (highest efficacy, 59% pain-free at 2 hours, onset within 15 minutes) or intranasal formulations (sumatriptan 5–20 mg, zolmitriptan nasal spray). 1

Antiemetic Adjuncts

• Metoclopramide 10 mg IV or prochlorperazine 10 mg IV provide direct analgesic effects through central dopamine receptor antagonism beyond their antiemetic properties, and should be given 20–30 minutes before or with NSAIDs for synergistic analgesia. 1
• Metoclopramide is contraindicated in pheochromocytoma, seizure disorders, GI bleeding, and GI obstruction. 1
• Prochlorperazine is contraindicated in CNS depression, pheochromocytoma, seizure disorders, GI obstruction, and concurrent adrenergic blocker use; it carries risk of QT prolongation and tardive dyskinesia with prolonged use. 1

Intravenous "Migraine Cocktail" for Severe Attacks

• First-line IV combination: Metoclopramide 10 mg IV PLUS ketorolac 30 mg IV provides rapid relief with minimal rebound headache risk. 1
• Alternative IV option: Dihydroergotamine (DHE) 0.5–1.0 mg IV (maximum 2 mg/day) has good evidence as monotherapy but is contraindicated with concurrent triptan use within 24 hours, beta-blockers, uncontrolled hypertension, coronary artery disease, pregnancy, and sepsis. 1

Third-Line Options (When Triptans Contraindicated or Ineffective)

• CGRP antagonists (gepants): Ubrogepant 50–100 mg or rimegepant 75 mg are recommended when triptans fail or are contraindicated due to cardiovascular disease; limit to ≤8 attacks per 30 days. 1, 2
• Ditans: Lasmiditan 50–200 mg (5-HT1F agonist without vasoconstriction) is safe in cardiovascular disease but requires an 8-hour driving restriction due to CNS effects. 1

Medications to Absolutely Avoid

• Opioids (codeine, hydromorphone, morphine, tramadol) and butalbital-containing compounds are contraindicated because they provide questionable efficacy, carry high dependence risk, cause rebound headaches, and worsen long-term outcomes. 1

Critical Frequency Limitation

• Limit ALL acute medications to ≤2 days per week (≤10 days per month) to prevent medication-overuse headache, which paradoxically increases headache frequency and can lead to chronic daily headache. 1
• If acute treatment is needed more than twice weekly, immediately initiate preventive therapy. 1

---

Preventive Medication

Indications for Starting Prevention

• ≥2 migraine attacks per month causing disability lasting ≥3 days. 3
• Acute medication use >2 days per week. 3
• Failure of, contraindication to, or intolerable side effects from acute treatments. 3
• Uncommon migraine subtypes (hemiplegic migraine, prolonged aura, migrainous infarction). 3
• Patient preference for preventive approach. 3

First-Line Preventive Medications

• Propranolol 80–240 mg/day (FDA-approved, strongest traditional evidence; doses <160 mg/day are generally sub-therapeutic). 3
• Topiramate 50–100 mg/day (typically 50 mg twice daily)—the only oral preventive with robust RCT evidence specifically for chronic migraine; preferred when obesity is present due to weight-loss effect. 3
• Candesartan (angiotensin-receptor blocker)—especially useful when hypertension coexists. 3
• Alternative beta-blockers: timolol 20–30 mg/day, metoprolol, atenolol, nadolol, bisoprolol. 3

Second-Line Preventive Medications

• Amitriptyline 30–150 mg/day—preferred for comorbid depression, anxiety, sleep disturbance, or mixed migraine/tension-type headache (lacks robust RCT evidence specifically for chronic migraine). 3
• Flunarizine 5–10 mg once daily (where available)—effective second-line agent but contraindicated in Parkinsonism or active depression. 3
• Divalproex sodium 500–1500 mg/day or sodium valproate 800–1500 mg/day—effective but strictly contraindicated in women of childbearing potential due to teratogenic risk; common adverse effects include weight gain, hair loss, and tremor. 3

Third-Line Options for Refractory Migraine

• CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab)—consider after failure of 2–3 oral preventives; efficacy requires 3–6 months for assessment; annualized cost $5,000–$6,000. 3
• OnabotulinumtoxinA (Botox) 155–195 U across 31–39 sites every 12 weeks—the only FDA-approved preventive specifically for chronic migraine (≥15 headache days/month); efficacy requires 6–9 months for assessment; contraindicated for episodic migraine. 1, 3

Implementation Principles

• Start at low dose and titrate slowly to target therapeutic dose over several weeks to minimize adverse effects. 3
• Allow an adequate trial of 2–3 months at target dose before judging efficacy—immediate benefits are rare. 3
• If first preventive fails, switch to an alternative first-line agent—failure of one class does not predict failure of others. 3
• Reassess after 6–12 months of successful control to determine whether preventive therapy can be paused. 3

Contraindications to Specific Preventives

• Beta-blockers: asthma, heart block, severe peripheral vascular disease. 3
• Topiramate: requires effective contraception and folate supplementation in women of childbearing potential due to teratogenic risk. 4
• Valproate/divalproex: absolute contraindication in women of childbearing potential. 3

---

Lifestyle Measures and Non-Pharmacological Interventions

Trigger Identification and Avoidance

• Maintain a headache diary (paper or smartphone app) to track attack frequency, severity, duration, triggers, medication use, and treatment response—this improves accuracy of reporting and identifies modifiable triggers. 1
• Common modifiable triggers: sleep deprivation, stress, tobacco use, alcohol consumption, excessive caffeine intake (limit to ≤200 mg/day consumed before noon), skipped meals, dehydration. 1

Sleep and Hydration

• Maintain consistent sleep schedule with adequate hours (7–9 hours nightly). 5
• Ensure proper hydration throughout the day. 5

Physical Activity

• Encourage regular moderate-to-intense aerobic exercise. 5

Behavioral Interventions

• Cognitive-behavioral therapy, biofeedback, and relaxation training are effective adjuncts to medication or stand-alone treatments when medications are contraindicated. 3
• Neuromodulatory devices and acupuncture can be considered as adjuncts. 3

---

Special Populations

Children and Adolescents

• First-line acute treatment: Ibuprofen (weight-based dosing) taken at earliest sign of headache. 4, 5
• For moderate-to-severe attacks or ibuprofen failure: Sumatriptan nasal spray 5–20 mg (approved for ages 12–17), zolmitriptan nasal spray, rizatriptan ODT, or almotriptan oral. 4, 5
• Preventive therapy indications: ≥2 attacks/month with disability ≥3 days or acute medication use >2 days/week. 4, 5
• First-line preventive: Propranolol (best safety data in children); amitriptyline if propranolol contraindicated. 5
• Avoid topiramate, valproate, and candesartan in children due to potential adverse effects on growth, development, and cognition. 5

Pregnancy and Lactation

• Discuss teratogenic effects of topiramate and valproate before initiating therapy; advise effective contraception and folate supplementation. 4
• Valproate is strictly contraindicated in pregnancy due to teratogenic risk. 4, 3

---

Red Flags Requiring Urgent Evaluation

• Thunderclap headache (sudden, severe onset). 1
• Progressive worsening pattern. 1
• New neurological deficits or atypical aura. 1
• Recent head trauma. 1
• Fever with neck stiffness. 1
• Impaired memory or consciousness. 1
• Headache worsened by Valsalva maneuver or awakening from sleep. 5
• Abnormal neurological examination. 5

Obtain MRI (preferred) or CT when red flags are present—routine neuroimaging is not indicated for typical recurrent migraine without red flags. 1

---

Common Pitfalls to Avoid

• Do not abandon triptan therapy after a single failed attempt—try a different triptan or route before declaring treatment failure. 1
• Do not maintain sub-therapeutic doses of preventives (e.g., propranolol <160 mg/day) indefinitely—optimize dose before declaring failure. 3
• Do not discontinue preventive therapy prematurely—require 2–3 months at target dose before assessing efficacy. 3
• Do not allow patients to increase acute medication frequency in response to treatment failure—this creates medication-overuse headache; instead, transition to preventive therapy. 1
• Do not prescribe opioids or butalbital compounds for migraine—they worsen long-term outcomes. 1